Skip Navigation

JNCI Journal of the National Cancer Institute 2002 94(21):1600-1602; doi:10.1093/jnci/94.21.1600
© 2002 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Wang, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 94, No. 21, 1600-1602, November 6, 2002
© 2002 Oxford University Press

NEWS

Whatever Happened to . . . ? Looking Back 10 Years

Linda Wang

The first 150 words of the full text of this article appear below.

This is part of an occasional series that recalls some of the stories reported 10 years ago in the News section of the Journal.

In the July 15, 1992 issue of the Journal, the News announced the creation of the Office of Alternative Medicine (OAM)—now the National Center for Complementary and Alternative Medicine (NCCAM)—at the National Institutes of Health to evaluate and determine the effectiveness of alternative treatments for cancer and other diseases.

The OAM was a response to a government report showing that many patients with cancer were turning to alternative treatments without any information about the safety and effectiveness of these treatments.

Despite the need for such research, there was a great deal of skepticism among the scientific community, recalled Stephen C. Groft, Pharm.D., first acting director of the OAM and current director of the NIH Office of Rare Diseases. Many researchers were simply unfamiliar with complementary . . . [Full Text of this Article]

PSA Debate Still Unsettled

Split Societies


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 IOVSHome page
C. All-Ericsson, L. Girnita, A. Muller-Brunotte, B. Brodin, S. Seregard, A. Ostman, and O. Larsson
c-Kit-Dependent Growth of Uveal Melanoma Cells: A Potential Therapeutic Target?
Invest. Ophthalmol. Vis. Sci., July 1, 2004; 45(7): 2075 - 2082.
[Abstract] [Full Text] [PDF]